Myricetin is a naturally occurring flavonoid present in many fruits, vegetables, and medicinal plants. Its potential use in supporting or treating rheumatoid arthritis (RA) is primarily based on preclinical scientific studies, rather than traditional or folkloric use. Several in vitro and animal studies have demonstrated that myricetin exhibits anti-inflammatory and antioxidant properties, which may be beneficial in the context of RA, a disease characterized by chronic inflammation and oxidative stress in the joints.

Research has shown that myricetin can inhibit the production of pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6) and suppress the activation of NF-κB, a key regulator of inflammation. Some animal studies have reported that myricetin administration reduced joint swelling and tissue damage in models of arthritis. For example, a 2015 study in mice with collagen-induced arthritis found that myricetin treatment significantly reduced disease severity, joint inflammation, and bone erosion.

However, there are no robust clinical trials in humans evaluating myricetin as a treatment for RA. Most evidence is limited to laboratory and animal models, and the translation of these findings to human therapy is not yet established. Therefore, while there is some scientific rationale and preliminary evidence, the overall support for myricetin in RA remains weak and should be considered experimental.